Dissecting FMR1, the protein responsible for fragile X syndrome, in its structural and functional domains

RNA

Volumn 5, Issue 9, 1999, Pages 1248-1258

  Adinolfi, Salvatore ^a   Bagni, Claudia ^b   Musco, Giovanna ^a   Gibson, Toby ^c   Mazzarella, Lelio ^d   Pastore, Annalisa ^a  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b Dipartimento di Biologia MCA   (Italy)

^c EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^d Dipartimento di Chimica   (Italy)

Author keywords

FMR1; Fragile sites; Fragile X; Modular proteins; RNA binding proteins

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN; POLYGUANYLIC ACID; RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; FRAGILE X SYNDROME; MOLECULAR DYNAMICS; PEPTIDE MAPPING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN RNA BINDING; REACTION ANALYSIS; RNA ANALYSIS; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; BLOTTING, WESTERN; CIRCULAR DICHROISM; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NERVE TISSUE PROTEINS; PROTEIN BINDING; PROTEIN FOLDING; RECOMBINANT PROTEINS; RNA; RNA-BINDING PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032847774     PISSN: 13558382     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1355838299990647     Document Type: Article

References (44)

1. Abitbol M, Menini C, Delezoide AL, RhynerT, Vekemans M, Mallet J. 1993. Nucleus basalis magnocellularis and hippocampus are the major sites of FMR1 expression in the brain. Nature Genet 4:147-152.
2. Bardoni B, Sittler A, Shen Y, Mandel JL 1997. Analysis of domains affecting intracellular localization of the FMRP protein. Neurobiol Dis 4:329-336.
3. Brown V, Small K, Lakkis L, Feng Y, Gunter C, Wilkinson KD, Warren ST. 1998. Purified recombinant Fmrp exhibits selective RNA binding as an intrinsic property of the fragile X mental retardation protein. J Biol Chem 273:15521-15527.
4. Buckanovich RJ, Darnell RB. 1997. The neuronal RNA binding protein Nova-1 recognizes specific RNA targets in vitro and in vivo. Mol Cell Biol 17:3194-3201.
5. Corbin F, Bouillon M, Fortin A, Morin S, Rousseau F, Khandjian EW. 1997. The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. Hum Mol Genet 6:1465-1472.
6. Creighton TE. 1993. Proteins. New York: WH Freeman and Company.
7. De Boulle K, Ververk AJMH, Reyniers E, Vits L, Hendrickx J, Van Roy B, VanDenBos F, de Graaff E, Oostra BA, Willems PJA. 1993. Point mutation in the FMR1 gene associated with fragile X mental retardation. Nature Genet 3:31-35.
8. Dejgaard K, Leffers H. 1996. Characterization of the nucleic acid binding activity of KH domains: Different properties of different domains. Eur J Biochem 241:425-431.
9. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL. 1993. The FMR1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nature Genet 4:335-340.
10. Eberhart DE, Malter HE, Feng, Y, Warren ST. 1996. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet 5:1083-1091.
11. Engebrecht J, Roeder GS. 1990. MER1, a yeast gene required for chromosome pairing and genetic recombination, is induced in meiosis. Mol Cell Biol 70:2379-2389.
12. Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST. 1997. FMRP associates with polyribosomes as an mRNP, and the 1304N mutation of severe fragile X syndrome abolishes this association. Mol Cell 1:109-118.
13. Fridell RA, Benson RE, Hua J, Bogerd HP, Cullen BR. 1996. A nuclear role for the fragile X mental retardation protein. EMBO J 15:5408-5414.
14. Gibson TJ, Thompson JD, Heringa J. 1993. The KH domain occurs in a diverse set of RNA-binding proteins that include the antiterminator NusA and is probably involved in binding to nucleic acid. FEBS Lett 3:361-366.
15. Hagerman RJ. 1991. Physical and behavioral phenotype. In: Hagerman RJ, Silverman AC, eds. Fragile X syndrome: Diagnosis, treatment and research. Baltimore, Maryland: Johns Hopkins University Press, pp 3-88.
16. Imbert G, Feng Y, Nelson DL, Warren ST, Mandel JL. 1998. FMR1 and mutations in fragile X syndrome: Molecular biology, biochemistry and genetics. In: Warren ST, Wells RD, eds. Genetic instabilities and hereditary neurological diseases. New York: Academic Press, pp 27-53.
17. Kanamori H, Dodson RE, Shapiro DJ. 1998. In vitro genetic analysis of the RNA binding site of vigilin, a multi-KH-domain protein. Mol Cell Biol 18:3991-4003.
18. Kandjian E, Corbin F, Woerly S, Rousseau F. 1996. The fragile X mental retardation protein is associated with ribosomes. Nature Genet 12:91-93.
19. Kruse C, Gruenweller A, Willkimm DK, Pfeiffer T, Hartmann RK, Mueller PK. 1998. tRNA is entrapped in similar, but distinct, nuclear and cytoplasmic ribonuclear complexes, both of which contain vigilin and elongation factor 1α. Biochem J 329:615-621.
20. Kuegler S, Gruenweller A, Probst C, Klinger M, Mueller PK, Kruse C. (1996). Vigilin contains a functional nuclear localization sequence and is present in both cytoplasm and the nucleus. FEBS Lett 302:330-334.
21. Leffers H, Dejgaard K, Celis JE. 1995. Characterization of two major cellular poly(rC)-binding human proteins each containing three K-homologous (KH) domains. Eur J Biochem 230:447-453.
22. Macias MJ, Hyvonen M, Baraldi E, Schultz J, Sudol M, Saraste M, Oschkinat H. 1996. Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Nature 382:646-649.
23. Mandel JL, Heitz D. 1992. Molecular genetics of the fragile X syndrome: A novel type of unstable mutation. Curr Opin Gen Dev 2:422-430.
24. Markus MA, Hinck AP, Huang S, Draper DE, Torchia DA. 1997. High resolution structure of ribosomal protein L11-C76, a helical protein with a flexible loop that becomes structured upon binding to RNA. Nature Struc Biol 4:70-76.
25. Mattaj IW, Englmeier L 1998. Nucleocytoplasmic transport: The soluble phase. Annu Rev Biochem 67:265-306.
26. Musco G, Kharrat A, Stier S, Fraternali F, Gibson TJ, Nilges M, Pastore A. 1997. The solution structure of the first KH domain of FMR1, the protein responsible for fragile X syndrome. Nature Struc Biol 4:712-716.
27. Musco G, Stier G, Joseph C, Castiglione Morelli MA, Nilges M, Gibson TJ, Pastore A. 1996. Three-dimensional structure and stability of the KH domain: Molecular insights into the fragile X syndrome. Cell 85:237-245.
28. Nakielny S, Dreyfuss G. 1997. Nuclear export of proteins and RNAs. Curr Opin Cell Biol 9:420-429.
29. Nakielny S, Fischer U, Michael WM, Dreyfuss G. 1997. RNA transport. Annu Rev Neurosci 20:269-301.
30. Pieretti M, Zhang F, Fu YH, Warren ST Oostra BA, Caskey CT, Nelson DL. 1991. Absence of expression of the FMR1 gene in fragile X syndrome. Cell 66:817-822.
31. Puglisi JD, Chen L, Blanchard S, Frankel AD. 1995. Solution structure of a bovine immunodeficiency virus tat-TAR peptide-RNA complex. Science 270:1200-1203.
32. Rost B, Sander C. 1993. Improved prediction of protein secondary structure by use of sequence profiles and neural networks. Proc Natl Am Soc 90:7558-7562.
33. Siomi H, Choi MC, Siomi MC, Nussbaum RL, Dreyfuss G. 1994. Essential role for KH domains in RNA binding: Impaired RNA binding by a mutation in the KH domain of FMR1 that causes fragile X syndrome. Cell 77:33-39.
34. Siomi H, Matunis MJ, Michael WM, Dreyfuss G. 1993b. The pre-mRNA binding K protein contains a novel evolutionary conserved motif. Nucleic Acids Res 27:1193-1198.
35. Siomi H, Siomi MC, Choi MC, Nussbaum RL, Dreyfuss G. 1993a. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74:1193-1198.
36. Siomi MC, Siomi H, Sauer WH, Srinivisan S, Nussbaum RL, Dreyfuss G. 1995. FXR1, an autosomal homolog of the fragile X mental retardation gene. EMBO J 14:2401-2408.
37. Siomi MC, Zhang Y, Siomi H, Dreyfuss G. 1996. Specific sequences in the fragile X syndrome protein FMR1 and FXR proteins mediate their binding to 60S ribosomal subunits and the interactions among them. Mol Cell Biol 16:3825-3832.
38. Sittler A, Devys D, Weber S, Mandel JL. 1996. Alternative splicing of exon 14 determines nuclear or cytoplasmic localization of FMR1 protein isoforms. Hum Mol Genet 5:95-102.
39. Swanson MS, Dreyfuss G. 1988. Classification and purification of proteins of heterogeneous nuclear ribonucleoprotein particles by RNA-binding specificities. Mol Cell Biol 5:2237-2241.
40. Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F, Higgins DG. 1997. The CLUSTALX windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res 25:4876-4882.
41. Urlaub H, Kruft V, Bischof O, Mueller EC, Wittmann-Liebold B. 1995. Protein-rRNA binding features and their structural and functional implications in ribosomes as determined by cross-linking studies. EMBO J 14:4578-4588.
42. Verkerk AJMH, Pierretti M, Sutcliffe JS, Fu YH, Kuhl DPA, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang F, Eussen BE, van Ommen GJB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galijaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST. 1991. Identification of a gene (FMR1) containing a GCC repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-914.
43. Yang YYL, Yin GL, Darnell RB. 1998. The neuronal RNA-binding protein nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci USA 95:13254-13259. Cell 65:905-914.
44. Yang YYL, Yin GL, Darnell RB. 1998. The neuronal RNA-binding protein nova-2 is implicated as the autoantigen targeted in POMA patients with dementia. Proc Natl Acad Sci USA 95:13254-13259. Cell 65:905-914.